[Clofibrate treatment of hyperlipoproteinemia].
Clofibrate has cholesterol- and triglyceride-lowering effect. They affect on the various points in the metabolic pathway of lipoproteins. They improve VLDL-synthesis in liver and increase the activity of LPL and hepatic TG lipase. As the results, HDL-cholesterol increases and LDL decreases. Therefore Clofibrate decreases not only plasma triglyceride but cholesterol levels. It has been reported that Clofibrate have a preventive effect on cardiovascular disease. So these agents are useful in the treatment for hyperlipidemic patients with or without atherosclerosis.
Third Department of Internal Medicine, Tohoku University School of Medicine.
S
S
Oikawa
H
H
Midorikawa
D002784:Cholesterol / Q000378:metabolism; D002994:Clofibrate / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism
D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D008071:Lipoprotein Lipase; D002994:Clofibrate